Featured Study: REIMAGINE
Since discovering in 2015 that Rifaximin is an effective treatment for IBS, we’ve shown how IBS can develop from food poisoning, and developed a blood test to diagnose IBS. Now we are developing therapies for methanogens and therapies for short bowel syndrome.
We discovered the efficacy of the cholesterol lowering drug lovastatin for improving IBS-C by inhibiting enzymes that assist in methane production.
We are accelerating the development of innovations that will lead to faster diagnostics for patients. We developed the only breath test to measure hydrogen, methane and hydrogen sulfide to help diagnose and differentiate between small intestinal bacterial overgrowth (SIBO), intestinal methanogenic overgrowth (IMO) and diarrhea.
We are now focusing on creating diagnostics for various microbiome disorders that are being discovered through the REIMAGINE platform and this will be the future of diagnostics coming out of MAST.